The pharmacologic blockade of NOS function for cancer therapy has been widely tested in preclinical and clinical settings [21, 50, 51]; however, our study suggests that close attention should be given when targeting all NOS isoforms as a therapeutic intervention for CRC. Here, NOS2 is linked to cancer.